Published in Breast Cancer Res Treat on January 01, 2006
Unleashing the therapeutic potential of NOD-like receptors. Nat Rev Drug Discov (2009) 1.39
NOD-Like Receptors: Master Regulators of Inflammation and Cancer. Front Immunol (2014) 0.97
NOD2: ethnic and geographic differences. World J Gastroenterol (2006) 0.89
NOD2 Polymorphisms and Their Impact on Haematopoietic Stem Cell Transplant Outcome. Bone Marrow Res (2012) 0.89
NOD2 polymorphisms associated with cancer risk: a meta-analysis. PLoS One (2014) 0.83
Low-risk Genes and Multi-organ Cancer Risk in the Polish Population. Hered Cancer Clin Pract (2006) 0.78
Multidrug-Resistance Related Long Non-Coding RNA Expression Profile Analysis of Gastric Cancer. PLoS One (2015) 0.77
Genetic Variability as a Regulator of TLR4 and NOD Signaling in Response to Bacterial Driven DNA Damage Response (DDR) and Inflammation: Focus on the Gastrointestinal (GI) Tract. Front Genet (2017) 0.75
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 17.30
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (2011) 6.77
Lung cancer susceptibility locus at 5p15.33. Nat Genet (2008) 5.99
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol (2007) 4.94
GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science (2013) 4.71
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol (2012) 4.44
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol (2009) 4.19
Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet (2009) 3.89
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res (2006) 3.81
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med (2008) 3.76
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet (2012) 3.04
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst (2008) 2.78
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
A range of cancers is associated with the rs6983267 marker on chromosome 8. Cancer Res (2008) 2.43
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet (2008) 2.33
Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet (2011) 2.29
Planning the human variome project: the Spain report. Hum Mutat (2009) 2.22
Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax (2006) 2.18
Combined analysis of three Lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriers. Int J Cancer (2012) 2.15
International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer (2008) 2.13
The NOD2 3020insC mutation and the risk of colorectal cancer. Cancer Res (2004) 2.01
A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer (2004) 1.96
Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol (2011) 1.94
Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med (2007) 1.91
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat Genet (2011) 1.84
Common variants at 6p21.1 are associated with large artery atherosclerotic stroke. Nat Genet (2012) 1.81
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res (2012) 1.81
Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 1.78
A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn (2009) 1.76
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev (2007) 1.75
The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. Hum Mol Genet (2010) 1.73
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
A genome-wide association study of upper aerodigestive tract cancers conducted within the INHANCE consortium. PLoS Genet (2011) 1.68
Polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways and endometrial cancer risk. Cancer Epidemiol (2010) 1.63
Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology (2004) 1.62
A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res (2004) 1.60
Age of diagnosis of colorectal cancer in HNPCC patients is more complex than that predicted by R72P polymorphism in TP53. Int J Cancer (2006) 1.60
Early radiation exposures and BRCA1-associated breast cancer in young women from Poland. Breast Cancer Res Treat (2008) 1.59
Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol (2008) 1.57
Four novel Loci (19q13, 6q24, 12q24, and 5q14) influence the microcirculation in vivo. PLoS Genet (2010) 1.57
Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples. J Allergy Clin Immunol (2011) 1.57
Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation. J Clin Oncol (2013) 1.52
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) 1.51
MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood. PLoS One (2010) 1.49
Potential association of vitamin D receptor polymorphism Taq1 with multiple sclerosis. Mult Scler (2011) 1.47
BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. Breast Cancer Res Treat (2011) 1.46
Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res (2008) 1.44
Colorectal cancer susceptibility loci on chromosome 8q23.3 and 11q23.1 as modifiers for disease expression in Lynch syndrome. J Med Genet (2010) 1.42